keyword
MENU ▼
Read by QxMD icon Read
search

Latest Antiparkinson's drugs

keyword
https://www.readbyqxmd.com/read/17029259/longitudinal-study-of-the-motor-response-to-levodopa-in-parkinson-s-disease
#1
COMPARATIVE STUDY
Benjamin G Clissold, Craig D McColl, Katrina R Reardon, Mark Shiff, Peter A Kempster
In this prospective study of 34 patients with Parkinson's disease, measurements of the short duration levodopa motor response have been performed in defined off states at 3 yearly intervals over a mean period of 11.4 years from the point of commencement of levodopa treatment. Twenty-two patients were still available for study; 10 had died and 2 were lost to follow-up. The levodopa motor response amplitude increases over the first 5 years of treatment, and thereafter, on and off scores worsen in parallel with conservation of the response...
December 2006: Movement Disorders: Official Journal of the Movement Disorder Society
https://www.readbyqxmd.com/read/16927880/-molecular-mechanisms-of-the-neuroprotective-effect-of-deprenyl
#2
REVIEW
Melinda Pálfi, Eva Szökó, Magyar Kálmán
(-)-Deprenyl, the irreversible inhibitor of monoamine oxidase B, has been used for decades in the therapy of Parkinson's disease. It improves parkinsonian symptoms due to its dopamine potentiating and antioxidant properties and presumedly delays disease progression. Its complex pharmacological action cannot be explained solely by its monoamine oxidase B inhibitory property. Recently, (-)-deprenyl has been demonstrated to exert antiapoptotic, neuroprotective effects on a number of in vitro and in vivo models in a dose significantly lower than required for monoamine oxidase B inhibition...
July 9, 2006: Orvosi Hetilap
https://www.readbyqxmd.com/read/16828805/msa-c-is-the-predominant-clinical-phenotype-of-msa-in-japan-analysis-of-142-patients-with-probable-msa
#3
MULTICENTER STUDY
Ichiro Yabe, Hiroyuki Soma, Asako Takei, Naoto Fujiki, Tetsuro Yanagihara, Hidenao Sasaki
We investigated the clinical features and mode of disease progression in 142 patients with probable multiple system atrophy (MSA) according to the Consensus Criteria. The subjects included 84 men and 58 women with a mean age at onset of 58.2+/-7.1 years (range: 38-79 years). Cerebellar signs were detected in 87.3% of these patients at the time of initial examination, and were found in 95.1% of them at latest follow-up. MSA-C was diagnosed in 83.8% of the patients at their first examination. Parkinsonism was initially detected in 28...
November 15, 2006: Journal of the Neurological Sciences
https://www.readbyqxmd.com/read/15598069/decrease-of-antiparkinsonian-drugs-before-start-of-an-antipsychotic-in-patients-on-levodopa-treatment
#4
COMPARATIVE STUDY
David A M C van de Vijver, Raymund A C Roos, Paul A F Jansen, Arijan J Porsius, Anthonius de Boer
INTRODUCTION: Antiparkinsonian drugs can induce behavioural disturbances, which should be treated by first reducing antiparkinsonian drugs and/or starting a benzodiazepine. If this approach fails, then antipsychotics can be considered. The aim of this study was to determine how often antiparkinsonian drugs are decreased and benzodiazepines are started in levodopa users before start of an antipsychotic drug. METHODS: Data came from the PHARMO database, which includes drug dispensing records for all residents of six Dutch cities...
October 2004: Pharmacy World & Science: PWS
https://www.readbyqxmd.com/read/10528328/-recent-advances-in-parkinson-disease
#5
REVIEW
I Litvan
OBJECTIVE: To evaluate the latest advances in the diagnosis and symptomatic pharmacological treatment of patients with Parkinson's disease at different stages. DEVELOPMENT: In this article we summarize the criteria for clinical diagnosis of Parkinson's disease based on recent clinico-pathological studies. We evaluate the different therapeutic options at early and late stages of the illness in view of the results of recent, controlled, double-blind studies in which the efficacy of new dopaminergic agonists (carbergolin, pramipexol and ropinirol) and catechol-O-methyl-transferase enzyme inhibitors (COMT; entacapone and tolcapone) are compared with placebo and with established treatments (e...
July 16, 1999: Revista de Neurologia
https://www.readbyqxmd.com/read/10363326/-motor-complications-of-treatment-with-levodopa-in-parkinson-s-disease
#6
REVIEW
M García-Escrig, F Bermejo-Pareja
INTRODUCTION: Motor complications of treatment with levodopa affect more than 50% of patients after several years' treatment. This has a marked effect on patients with Parkinson's disease since these side effects are undesirable, affect the natural course of the disorder and complicate treatment. DEVELOPMENT: In this review we describe the main epidemiological, physiopathological and therapeutic aspects of the motor complications of levodopa. According to most epidemiological studies, starting treatment at an early age and more severe degree of the disorder are the main risk factors...
April 16, 1999: Revista de Neurologia
1
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"